The association between IL-10 and Diabetic Mellitus: Review

Noora Wael Rasheed

Department of Medical Laboratory Techniques, Al Rafidain University College
Noora.waal@ruc.edu.iq

ABSTRACT

Cytokines regulate a variety of biological functions, both immunologic and non-immunologic, and are generated by multiple cell types and act at various phases of cellular proliferation and differentiation. IL-10 is an immunoregulatory cytokine that possess simultaneously immunosuppressive and immunostimulatingeffects and is essential for reducing inflammatory overreactions and autoimmune diseases. Diabetes mellitus is a metabolic condition caused by problems in insulin production, insulin action, or both, with acute consequences such as hypoglycemia, ketoacidosis, or non-ketotic hyperosmolar coma. Long-term effects include renal failure, nerve damage, and blindness. Whereas diabetes mellitus is defined by a gradual decrease of -cell insulin production against the backdrop of insulin resistance, type 1 diabetes is a chronic autoimmune illness marked by insulin insufficiency. A medical disorder called type 2 diabetes is brought on by consuming too much food energy. Diabetic can be correlated with a high level of cytokines that act as pro-inflammatory and also anti- inflammatory, such IL-6 and IL-10, respectively. The IL-10 (1082) G/A gene polymorphism is linked to T2DM and may be protective against T2DM.

Keywords: IL-10, UTI, DM, TYK2, JAK1, STAT3

Introduction

Cytokines

Neutrophils, which phagocytose and destroy bacteria, are an example of an immune defense mechanism that may be non-specifically targeted against a large variety of pathogens or particularly targeted against a single organism (e.g. antibody –mediated inactivation of the organism) (Marshall et al., 2018). A network of tiny, soluble, intercellular regulatory proteins known as cytokines, which regulate a variety of biological functions, both immunologic and non-immunologic, is responsible for the creation and maintenance of these immunological responses(Kany et al., 2019). A variety of target cells are acted upon by several cytokines, which are generated by multiple cell types and act at various phases of cellular proliferation and differentiation (Catalán et al., 2021). They all attach to certain receptors that are expressed on the target cell's surface (Taban et al., 2022). Hence, they set off intricate intracellular signaling processes that regulate the gene expression needed for the cellular response (R. M. Morris et al., 2022). Since they often have an impact on cells that are next to one another, cytokines mostly have a paracrine effect (Hanahan, 2022). Moreover, they may function remotely (endocine), and they may have autocrine effects on the cell of origin. It is difficult to categorize the molecules since each cytokine has a number of overlapping activities and each activity may be mediated by more than one cytokine (Hazrati et al., 2022; Sung et al., 2021). Functionally speaking, inflammatory cytokines may be divided into proinflammatory and antiinflammatory types, such as IL-1 and IL-6

and IL-10 (Mascaux et al., 2019). As most cytokines may be generated by a number of cell types depending on the stimulating factor and interaction with other cells, it has proven challenging to maintain this categorization (Molnar et al., 2021).

Interleukins

Leukocytes create these cytokines, which then affect leukocytes. They contribute to the activation, differentiation, and proliferation of immune cells (Qiu et al., 2021). For instance, interleukin-2 (IL-2) increases T cell expansion and activation whereas interleukin-4 (IL-4) encourages T cell differentiation into Th2 cells(S. Waters et al., 2018) .

Interleukin-10 (IL-10)

One of the strongest pleiotropic cytokine is IL-10. It was first identified by Fiorentino (1989) as a substance that prevents T helper (Th) 1 cell clones from producing interferon (IFN). Originally known as cytokine production inhibitor factor, the new cytokine was eventually renamed to IL-10 (Vazquez et al., 2015). While IL-10 mostly has immunosuppressive effects, it also possesses immunostimulatory characteristics (Briukhovetska et al., 2021). It is essential in reducing inflammatory overreactions and autoimmune diseases. The IL-10 belong to class II cytokine family, which also includes interferons (Zhang et al., 2021).

Structure of IL-10 and its receptor

Interleukin-10 consisting of same polypeptidechains of 160 aminoacids each and a Mw about 18.6 kDa (hIL-10) (Hong et al., 2021). Both subunits that are not covalently bonded combine to form a homodimer. Two intra-chain disulfide bonds are present in each subunit, one between residues 12 and 108 and the other between residues 62 and 114 (Fass & Thorpe, 2018). The atomic structure of hIL-10 reveals that each componentis composed of six spiral segments (A to F) and their relating loops, shown in figure (1) (Giastas et al., 2018). The overlap of helices E and Fmaintains the non-covalent dimeric structure. In terms of its dimer architecture, IL-10 and IFN- have a lot of similarities. According to Ruiz-Gómez et al. (2016), the apparent isoelectric point of natural IL-10 is pH 8.2.



Figure (1); N and C terminal of the IL-10 ribbon (Minshawi et al., 2020a)**.**

Comprehensive cellular reactions to IL-10 need the successive construction of several proteins of the two unique IL-10R1 and IL-10R2 are class II cytokine trans-membrane-receptor subunits found on the cell surface.e (Porro et al., 2020). IL-10 initially forms a highly-affinity bond with IL-10R1 (Nagata & Nishiyama, 2021). In response to this interaction, IL-10 undergoes a conformational shift that controls the low-affinity binding of IL-10R2, leading to the creation of a ternary receptor complex (Peruzzaro et al., 2019; Schülke, 2018). The whole receptor complex's structure is yet unknown. For the one to double combination of hIL-10 with the extracellular, the part of IL-10R that are water-soluble, only one crystal structure is presently known (Sung et al., 2006 ; Martin & Griffin, 2018).

Biology of IL-10

The ternary receptor complex is formed after receptor engagement, which then activates the JAK/STAT signaling pathway to cause IL-10 to have biological effects (figure 2) (Peruzzaro et al., 2019). Tyrosine kinase 2 (TYK2) and Janus kinase 1 (JAK1) are first turned on. They phosphorylate certain tyrosine reminders of the intracellular portion of IL-10R1 as well as themselves (R. Morris et al., 2018). Thereafter, STAT3 (a signal transducer and transcription activator) attaches to these tyrosine residues (Madani et al., 2021). Activation of STAT3 follows phosphorylation. Moreover, STAT1 molecules are activated, and STAT5 molecules are also active in certain cells. These transcription factors create homo- and heterodimers (Loh et al., 2019).



Figure (2); Signaling pathways shown schematically that activate STAT3. Able hance the rate at which STAT3 protein is phosphorylated (shown by red arrows) (marked with P) -P-STAT3
(Jaśkiewicz et al., 2020)

The reduction of nuclear factor B (NF-B) DNA binding and translocation, as well as the inhibition of B kinase inhibitor activity, are key components of IL-10-mediated immunosuppression (Liu et al., 2017). Moreover, by blocking the translation of MyD88, IL-10 prevents the production of proinflammatory mediators that are activated by Toll-like receptors (TLR) (Sartorius et al., 2021; Vijay, 2018). Virtually every leukocyte in the human bodyproduce IL-10. It was first identified as a secreted factor by Th2 cells (Ouyang & O'Garra, 2019). Other significant cell sources for IL-10 are monocytes and macrophages, granulocytes include DC, B-cells, NK cells, as well as eosinophilic are all capable of producing it (Liu & Gack, 2020). Depending on the kind of tissue and the precise immunological activation, IL-10 concentration varies locally. Many endogenous and exogenous Stimulants, such as catecholamines and lipopolysaccharide, have a role in the initiation and maintenance of inflammation.(LPS), cause monocytes and macrophages to secrete IL-10 (Kologrivova et al., 2021). IL-10's biological effects are very varied and complicated. The primary target cells of the inhibitory actions of IL-10 are

monocytes and macrophages (Asami & Shimizu, 2021). Patients with psoriasis' peripheral blood mononuclear cells (PBMCs) show upregulation of 1600 genes and downregulation of 1300 additional genes in response to IL-10 therapy (Kutwin et al., 2021). Monocytes and macrophages' active, pro-inflammatory roles in innate and acquired immunity are mostly suppressed by IL-10, but their inhibitory, tolerance-inducing actions are strengthened (El-Zayat et al., 2019). Phagocytosis, antigen presentation, and the release of immune mediators are all impacted (Z. Wang et al., 2021). On a transcriptional level, IL-10 inhibits the synthesis anti-IL-1 receptors and the receptor of TNF that is soluble act as an anti-inflammatory agents, in addition to the predominantly pro-inflammatory cytokines IL-1, IL-6, IL-8, TNF, and GM-CSF (Amarante-Mendes et al., 2018; El-Zayat et al., 2019). IL-10 restricts macrophages and monocytes from presenting antigens by decreasing both constitutive and IFN-related-MHC class II surface proteins (Schoggins, 2019). IL-10 inhibits the differentiation of monocytes into dendritic cells while promoting the maturation of macrophages (Mittal & Roche, 2015). Other cell types are also affected by IL-10, such as T cells. Both type 1 and type 2 CD4+ cells' proliferation and production of cytokines are inhibited by it. IL-10 prevents the production of various pro-inflammatory cytokines brought on by LPS in neutrophilic and eosinophilic granulocytes (Keegan et al., 2021).

Moreover, IL-10 prevents neutrophils from producing cyclooxygenase-2, which in turn prevents the creation of the proinflammatory prostaglandin E2 (Fitzgerald & Kagan, 2020). Moreover, mast cells' generation of nitric oxide and inflammatory cytokines is inhibited by IL-10, both naturally occurring and in response to antigens (Catalán et al., 2021). IL-10 also prevents the production immunoglobulin type E receptors. In addition to its inhibitory effects, IL-10 also stimulates certain immune cells (Galli & Tsai, 2012). For instance, it increases the toxic activity of NK cells as well as IL-2-dependent multiplying and cytokine fusing. Moreover, it promotes B cell proliferation, MHC II expression, and plasma cell differentiation (Chu et al., 2022).

Many infections have been demonstrated to take use of IL-10's immunosuppressive properties for their own purposes. The encoding of viral IL-10s, or orthologs of IL-10, is the result of co-evolution of viruses with their hosts (Carty et al., 2021). These orthologs seem to have been acquired by several viruses independently from their hosts (Eberhardt et al., 2016). At least 21 viruses have been shown to contain viral IL-10 orthologs, including both the cytomegalo-virus and EPV IL-10s have a bio-activity outline that is more confined to immunosuppressive actions than their cellular orthologs (Poole et al., 2020). It is widely known that other infections take advantage of IL-10's actions. Human immune cells produce IL-10 when infected with the bacteria carried by ticks Borrelia burgdorferi, which seems to decrease immunological functions necessary for the early management of the infection, increasing the likelihood that the bacteria would resist clearance and stay in the host. In order to avoid immune system clearance, parasitic worms also cause the host to express IL-10 (Coburn et al., 2021). On the contrary, there is strong sign that increased IL-10 level may help to lessen the severe systemic effects brought on by diseases like malaria. Also, it was shown that IL-10 was crucial in the development of a number of non-infectious disorders (Martinez-Espinosa et al., 2021). These illnesses may be further separated into those linked to IL-10 overproduction and those linked to IL-10 deficiency. The evolution ofmelanoma and Lupus erythematosus seems to be aided by elevated IL-10 concentrations. Patients with lupus erythematosus had higher densities of IL-10-producing cells, and this increment correlated with disease severity (Biswas et al., 2022).

Anti-IL-10 antibody-treated individuals also showed a decrease in disease activity. These clinical results were mostly related to the endothelial cells' lower production of multiple activation indicators and PBMCs' diminished spontaneous release of these signals (X. Wang et al., 2019a). Human melanoma cells respond

to IL-10 as a growth factor, which suggests that it has tumor-promoting properties. Yet, IL-10 plays a variety of intricate and poorly known roles in the onset and spread of cancer (H. Zhao et al., 2021). IL-10 may help malignant cells avoid immune surveillance by tumors because it causes immunosuppression. On the other hand, IL-10 has effects on tumors that are both proliferative and inhibitory, such as in breast cancer (Sheikhpour et al., 2018). It has even become a novel prospective medication for immune intervention in cancer since it encourages immunological monitoring for tumors and reduces harmful Cancer-related inflammation (Gonzalez et al., 2018). PEGylated IL-10 shown evidence of anticancer efficacy In cases of advanced solid tumors in patientsin a phase I research. The recruitment stage of a phase III study is investigating PEGylated IL-10 in conjunction using chemotherapy for advanced pancreatic cancer(Autio & Oft, 2019). The continuous overshooting immunological activation that results with IL-10 deficiency, whether absolute or relative, results in chronic inflammation. This is true, for instance, of multiple sclerosis and autoimmune illnesses like psoriasis and inflammatory bowel disease (IBD) (Bezzio et al., 2022). In contrast to other inflammatory dermatoses, psoriatic skin lesions showed little IL-10 mRNA expression. Also, patients receiving traditional anti-psoriatic medication had increased IL-10 expression by PBMCs, suggesting that IL10 has an anti-psoriatic effect (Uttarkar et al., 2019). Moreover, there is evidence that IL-10 deficiency contributes to multiple sclerosis Patients' B-cells were discovered to have a diminished ability to generate IL-10. In conclusion, the innate and adaptive immune systems are both suppressed by the powerful immune suppressor IL-10. It is a strong anti-inflammatory mediator that limits immune responses and may stop tissue damage brought on by excessive and protracted inflammatory immune responses. Contrarily, IL-10 also has immunostimulatory properties. Complex IL-10 actions depend on the particular tissue and target cells (Li & Bar-Or, 2019).

Potential as an anti-inflammatory drug

IL-10 has been suggested as a possible medicine preparation for therapy of a number of diseases caused by the immune system (including autoimmune diseases), including rheumatoid arthritis, psoriasis, multiple sclerosis, type I diabetes, and IBD, because of its strong anti-inflammatory effects (Wang et al., 2019). As a result, significant efforts were made to investigate the (mainly systemic) therapeutic effectiveness of IL-10 against a number of these disorders. Nevertheless, inconsistent or negligible findings were found in the majority of trials that examined the systemic delivery of IL-10 to individuals with autoimmune disorders (Hou et al., 2022). The use of systemic IL-10 for The therapy for psoriasis, a chronic inflammatory conditioncondition of the skin in where do leukocytes travel from the blood arteries to the epidermis?produce papulosquamous plaques, has so far yielded the most encouraging results. The skin lesions include high amounts of proinflammatory cytokines including IFN- and TNF, while other dermatoses have lower concentrations of IL10. Patients in a phase II study received weekly subcutaneous (SC) injections of IL-10 (Bridgewood & Publisher, n.d.). Nine out of ten patients had anti-psoriatic effects, and both the afflicted region and illness index significantly decreased. Patients with persistent Subclinical psoriasis patients were given SC IL-10 injections for four months in a second placebo-controlled phase II study (Smith et al., 2019). In comparison to the placebo group, the IL-10-treated group saw considerably fewer relapses. While the exact processes of how IL-10 affects psoriasis are still unclear, impacts T lymphocytes and antigen-presenting cellsare likely to be a contributing factor. Contrarily, a placebo-controlled double-blind phase II experiment using psoriasis patients who received IL10 SC for 12 weeks revealed only a little clinical improvement in comparison to the control group, despite a definite change in the T cell response from the Th1 to the Th2 type being seen (Flammer et al., 2023).

Axons and myelin are irreversibly damaged in multiple sclerosis, a central nervous system

disorder that is chronically inflammatory and demyelinating and characterized by localized inflammatory lesions. The demyelination process is significantly influenced by autoreactive T and B cells, but IL-10-producing B cells help to reduce inflammatory reactions that promote myelin breakdown (Correale et al., 2019). Yet, the ability of B cells from MS patients to secrete IL-10 is compromised. Also, it has been shown that interferon therapy raises the blood levels of IL-10 in people with multiple sclerosis. Consequently, it was proposed that an increase in IL-10 production may be Interferon-'s beneficial mode of action in multiple sclerosis (Pennati et al., 2016).

Systemic IL-10 therapy is not presently believed to be a viable treatment for multiple sclerosis since it did not reduce demyelination in animal models of the illness. An inflammatory disease that mostly affects the joints, rheumatoid arthritis is characterized by synovial inflammation that destroys bone and cartilage, the development of autoantibodies, and, in certain cases, systemic inflammation (Yuan et al., 2019). TNF and other cytokines that promote inflammation,which boost inflammatory immune responses and are crucial in the degeneration of the joints, are the disease-causing agents. Due to its dual effects on illness by lowering inflammatory cytokines and increasing the humoral immune response, IL-10 seems to have a dual function in the illness (Amin et al., 2020). Monocytes and macrophages' production of IgG receptors is stimulated, which in turn promotes their tissue-damaging and pro-inflammatory activities. Patients with rheumatoid arthritis who received therapy with methotrexate and IL-10 exhibited a small clinical improvement compared to those who received just methotrexate, according to a clinical research (Yap et al., 2018). The work was put on hold, nonetheless, since IL-10 proved less effective than TNF antibodies at reducing rheumatoid arthritis symptoms. The ineffectiveness of IL-10 may have been due to its short half-life. Dekavil is a fusion protein made from an anti-fibronectin extra-domain A antibody and IL-10 that is now being tested in clinical settings. In the mouse model of collagen-induced arthritis, dekavil slows down the disease's course. 15 of 23 patients in a phase Ib clinical study of a methotrexate combo treatment had a therapeutic effect (Murer & Neri, 2019).

Stability of IL-10

Its significant vulnerability to acidic environments was first mentioned in the initial publication on IL-10. Very negligible bioactivity was still seen after 1 hour of incubation at pH 2. Because to their significantly lower susceptibility to acidic denaturation, additional cytokines could be distinguished early on as a result. This original finding was supported by further research, which revealed that IL-10's bioactivity in solution reduces when preincubated at pH levels below 6, with an apparent pKa value of about 4.8 (Tarique et al., 2020). The non-covalent dimer's irreversible dissociation and loss of activity are linearly connected. As the monomer is not bioactive, the maintenance of the dimer is necessary for IL-10 to remain bioactive. Syto et al. also looked at how temperature stress affected IL-10 solutions (Minshawi et al., 2020b). The dimer dissociated by 22% after heating at 55 degrees Celsius, IL-10 aqueous solution at 0.3 mg/ml for an hour as opposed. The generation of the monomer was increased to 55% and 10%, respectively, At 55 degrees Celsius, IL-10 aqueous solution at 0.3 mg/mlwas lowered to 0.05 mg/ml, showing that the pace of the dimer's dissociation is dependent on the starting concentration of IL-10 (Pestovsky & Martínez-Antonio, 2019). Once again, it was shown that the bioactivity of IL-10 was linearly correlated with the quantity of residual dimer. Moreover, each IL-10 molecule's four cysteines create two intact disulfide bridges that are necessary for maintaining the bioactivity of IL-10. Destabilized by the loss of these bonds, the protein's -helical composition drops from 60% to 53%. There is no in vitro biological activity for the decreased IL-10 (Sun et al., 2021).

Genetic of IL-10

The human IL-10 gene is found on chromosome 1 and has a molecular weight of 5 exons (5.1 kb). The pleiotropic immunoregulatory cytokine interleukin 10 (IL-

10) is mostly released by macrophages, although it is also produced by dendritic cells, cytotoxic T cells, B lymphocytes, monocytes, and mast cells (Trifunović et al., 2015). With its inhibitory impact on the production of MHC class II, costimulatory molecules like CD80 and CD86, IL-10 reduces the ability of monocytes and macrophages to deliver antigen to T cells, hence suppressing the expression of several cytokines. Three SNPs in the IL10 gene (A-1082G, C-819T, and A-592C) were previously linked to the prevalence of NHL in Polish individuals (Mahajan et al., 2008). They discovered that individuals with aggressive NHL had a considerably greater prevalence of the IL-10 lowproducing A-1082A homozygous genotype than did patients with indolent forms of the illness and controls. Moreover, individuals with more aggressive illness were found to have the AC genotype more commonly than patients with indolent forms and healthy controls. The AA homozygosity and the ACC genotype were shown to be separate risk factors for more virulent illness presentation in multivariate studies (Mahajan et al., 2008). Using SSP-PCR, a prior research examined the impact of the two SNPs (G1082A and C819T) on Egyptians' susceptibility to DLBCL. They found that patients with NHL had a noticeably higher GT haplotype. With D′ = 0.596 and r2 = 0.1032, a strong linkage disequilibrium between the SNPs 819 and 1082 was shown. In the same vein, a prior research that comprised 12 articles With over 5500 NHL instances and 7000 controlsin a meta-analysis. Both the homozygous and recessive of the IL10 C819T polymorphism and the recessive form of IL10 C-592A polymorphism were linked with a significantly lower chance of developing DLBCL, according to stratification studies (Almolakab et al., 2022).

Diabetic mellitus

Diabetes mellitus is a term used to describe a metabolic condition with numerous origins that is defined by high blood sugar levels and abnormalities in the metabolism of carbohydrates, fats, and proteins as a consequence of problems in insulin production, insulin action, or both. There is an internationally agreed-upon aim to stop the growth in diabetes and obesity by 2025. Type 2 diabetes, which is the most prevalent and often affects adults, is caused when the body doesn't produce enough insulin or develops resistant to it (American Diabetes Association Diagnosis and Calcification of Diabetes Care 2012).

If the condition is not sufficiently treated, acute consequences (hypoglycemia, ketoacidosis, or non-ketotic hyperosmolar coma) might develop. Cardiovascular disease, chronic renal failure, retinal damage (which may result in blindness), nerve damage (of many types), and microvascular damage, which may result in impotence and inadequate healing, are serious long-term effects. Inadequate wound healing, especially in the feet, may cause gangrene and need amputation (Association, 2009).

Several investigations have shown that pancreatic beta-cells suffer from prolonged hyperglycemia. It could be connected to glucotoxicity, a process that plays a role in the etiology of type 2 diabetic mellitus (DM) (Giri et al., 2018). The risk profile of the most of the consequences listed above may be reduced with proper diabetes management, as well as greater focus on blood pressure control and lifestyle variables (such as quitting smoking and maintaining a healthy weight). With time, the effects of diabetes mellitus may include renal failure, nerve damage, and blindness (WHO, 2020). Damage to tiny vessels, often known as microvascular disease, leads to this kind of damage.

Diabetes has a significant role in speeding the process of atherosclerosis, which results in the hardening and constriction of the arteries and causes stroke, coronary heart disease, and other diseases of the big blood vessels (Poznyak et al., 2020).

The medical term for this is macrovascular disease. Never base a diabetes diagnosis in a client who is asymptomatic on a single abnormal blood glucose reading. For the asymptomatic individual, at least one more plasma glucose test result from a sample taken while fasting, from a sample

taken from someone who should be experiencing symptoms, or from an oral glucose tolerance test, with a value in the diabetes range, is required (OGTT) (Genuth et al., 2018).

Diabetes mellitus types (DM)

The World Health Organization (WHO) in 2019 published the criteria that proposed four major classes of diabetes, and named them, table (1-1):

Table 1; classification of diabetic mllitus

Diabetic type	Description
Type 1 diabetes	It is a chronic autoimmune illness characterized by insulin insufficiency and may be caused by autoimmune - cell death. Throughout the last 25 years, type 1 diabetes knowledge has developed quickly, leading to a wide understanding of many facets of the condition (DiMeglio et al., 2018).
Type 2 diabetes	because of a persistent decline in -cell insulin production usually occurring in the context of insulin resistance.
Gestational diabetes mellitus (GDM)	Pregnancy-related diabetes that was not overtly present before to conception but was discovered in the second or third trimester.
Secondary diabetes	Examples of diabetes types caused by external factors.

Type 2 diabetes mellitus (T2DM)

Diabetes of adult onset, diabetes associated to obesity, and non-insulin-dependent diabetes were all formerly referred to as "type 2 diabetes," but now they are all referred to as "type 2." (NIDDM). While people with this kind may still manufacture some insulin, it is often not enough to meet their body's demands (Regina et al., 2022). The world's most common endocrine or metabolic disorder is type 2 diabetes mellitus. According to reports, prevalence ranges from low (3%) in certain groups, such rural Indians, to moderate (3–10%) in some European communities, high (11–20%) in some Arabic nations, to extremely high proportions (> 20%) in communities like the Pima Indians of Texas, USA (Fan, 2017).

The most recent update on Iraq's status in 2020 noted that it is one of the IDF MENA's 21 member countries and territories (Middle east and north Africa) In the MENA area alone, 55 million individuals already have diabetes, and by 2045, this number will have increased to 108 million worldwide. A significant aging-related rise in the incidence of DM has been shown by several epidemiological investigations.

Type 2 diabetes risk factors and signs

Obesity, a poor diet, a sedentary lifestyle, and advanced age are the main risk factors for type 2 diabetes; 21% of persons over 60 have a family history of the disease, and diabetes is a condition that often runs in families. Particularly in the first phases of the condition, not everyone with type 2 diabetes exhibits symptoms (Lin & Li, 2021). In actuality, 5.7 million of the 23.6 million individuals who have diabetes are completely uninformed of their condition. Of them, 90 to 95% have type 2 diabetes. Symptoms may not appear in people with type 2 diabetes for years or even decades, but as the condition worsens and blood sugar levels increase, symptoms appear (Kalra et al., 2018). The following symptoms and indicators are possible in people with type 2 diabetes:

1. Clouded vision
2. Diminished or numb feeling in the hands and feet
3. Dry skin that itches
4. Constant urge to urinate » recurring vaginal and bladder infections
4. More hunger and thirst
6. Male infertility (erectile dysfunction)
7. Cuts or sores that heal slowly
8. Tiredness

living style

Type 2 diabetes epidemiological research show that excessive eating, particularly when paired with obesity and inactivity, is linked to the development of the disease. By changing your diet and increasing your physical activity, you may often lower your chance of developing type 2 diabetes. The risk of developing insulin resistance and diabetes is decreased by diets that are very low in saturated fats (Kalra et al., 2018). It is well recognized that a variety of lifestyle variables play a significant role in the development of type 2 diabetes. Diabetes is 82% less common among those who engage in a lot of physical exercise, eat well, don't smoke, and drink in moderation. Moreover, the rate was 89% lower when a typical weight was added (Kyrou et al., 2020).

Obesity

The medical disease referred to as obesity happens whenextra The accumulation of body fat may severely effect health, shortening life expectancy and increasing health problems. If a person has a body mass index (BMI) 30 or more can be considered as obese. which relates weight to height squared, is more than or equal to 30 kg/m2. Obesity raises the risk of several illnesses, including heart disease and type 2 diabetes (Palmer & Apovian, 2017). While there are a few instances where genes, endocrine diseases, drugs, or mental illness are the main causes, it is most often brought on by a combination of excessive dietary energy consumption, a lack of exercise, and hereditary vulnerability. When diagnosed with type 2 diabetes, 80% of individuals are obese. Many of these patients see a reduction in symptoms when they lose weight (Pillon et al., 2021).

Pregnancy

Hormones produced during pregnancy block the effect of insulin.

Age

The majority of people with type 2 diabetes are middle-aged or older. Around 70% of all instances of diabetes occur after the age of 50, and it affects 10% of the population over the age of 65.

Influence of IL-10 level and occurrence of diabetic mellitus

Micro and macro vascular problems, which are thought to be the main source of morbidity and death, provide the greatest danger to T2DM patients (Kosiborod et al., 2018). Several studies have shown that low-level chronic inflammation may have a major impact on the development and progression of T2DM (Oguntibeju, 2019). According to studies, T2DM complications are linked to elevated levels of pro- and anti-inflammatory cytokines, namely IL-6 and IL-10, in the plasma of T2DM patients (Chawla et al., 2016). The pleiotropic cytokine interlikun-6, which is linked to human chromosome 7p15-p21, is mostly produced by macrophages and T cells. It controls a variety of immunological processes, such as the creation of cell-binding molecules and acute phase proteins, and it makes it easier for other cytokines to be released in response to inflammatory stimuli. Moreover, it interacts with muscle, hepatocyte, and pancreatic cells to directly or indirectly change the balance and metabolism of glucose (Velazquez-Salinas et al., 2019). In reality, single nucleotide polymorphism variability varies amongst ethnic groups (SNPs). Hence, interindividual differences in cytokine gene expression result from polymorphism in the coding and non-coding regions. These differences in immunological responses therefore raise the risk of infection and the formation of a variety of chronic diseases (Zhao et al., 2017). Several investigations have shown a correlation between circulating IL-6 levels and the IL-6 promoter polymorphism (G174C) and the onset of many diseases (Hashad et al., 2021; Salari et al., 2021). Despite conflicting results, the impact of IL-6 gene polymorphism on the onset of T2DM is still unclear. Some individuals have remained dubious despite research showing a connection between susceptibility and who is most at risk of developing T2DM and the IL-6 -174 G/C polymorphism (Abdolmaleki et al., 2019; "Cardiovascular Disease and Risk Management," 2017; Ma et al., 2016). Moreover, research have shown that the 174 G/C polymorphism may be a predictor of the development of comorbidities such TB as

well as the advancement of problems, notably renal diseases in T2DM patients. Nevertheless, a few investigations found no connection between this mutation and diabetes-related kidney problems (Ayelign et al., 2021).

Interleukin-10 is a multifunctional cytokine having anti-angiogenic and immunosuppressive properties (IL-10). On chromosome 1q31–32, which has been genetically related to a number of autoimmune illnesses, including T2DM, is where the human IL-10 gene is found. The first sequence of the IL-10 gene promoter (nucleotide substitution: A1082G) would enhance transcription of both genes by about twice, increasing the amount of this cytokine produced (Halimi et al., 2022). This shows that the polymorphism genotype may be linked to a higher frequency of T2DM. T2DM prevalence is presently quickly rising throughout the globe, particularly in middle- and low-income nations like Ethiopia. With the rising prevalence of T2DM patients in Ethiopia, it is crucial for disease management and therapy to understand the genetic underpinnings and markers that contribute to the formation and progression of T2DM (Witka et al., 2019).

There was a very strong correlation between type 2 diabetes and the IL-10 gene G1082A polymorphism (Ayelign et al., 2021). Patients with type 2 diabetes mellitus were more likely to have the GG genotype than those who seemed to be in good health and had the AA and AG genotypes (P-value = 0.012, odds ratio = 0.30 and 0.40 (0.198-0.808), respectively). Despite this, those with the AA genotype were 0.3 times more likely to acquire T2DM than those with the AG genotype (Rodrigues et al., 2017). We conclude that the IL-10 (G1082A) variation may protect Ethiopians against type 2 diabetes. Results from studies conducted on Egyptian and Chinese populations linked the GG genotype of the IL-10 gene to be more likely to develop type 2 diabetes. In contrast to our results, a Brazilian study found no significant change in the IL-10 gene genotype and allele frequencies G1082A between the T2DM and control groups. Genetic polymorphism of cytokines like IL-6 and 10 causes up- or down-regulation of inflammatory cytokines to induce insulin resistance, which is one of the environmental or genetic causes of type 2 diabetes. Increased production of pro-inflammatory molecules is a common consequence of insulin resistance due to inadequate IL-10 synthesis or ineffective IL-10 signaling, especially in T2DM (Kang et al., 2019).

When comparing those without complications from their diabetes type 2 and healthy comparison patients, IL-10 levels were found to be considerably higher in the former group, according to a research published in the Journal Related Metabolic Disorders and Diabetes in 2014 (Kang et al., 2019). While this research did find a link between IL-10 and insulin resistance, it also revealed inconclusive evidence of a positive relationship IL-10 levels and insulin sensitivity. Subjects' IL-10 concentrations with type 1 diabetes were shown to be considerably lower as compared to baseline healthy subjects in 2019 research published in the Journal of Endocrinological Investigation. This study's authors hypothesize that diminished IL-10 levels contribute to the evolution of autoimmunity in type 1 diabetes (Sun et al., 2021).

As a whole, the correlation between IL-10 and diabetes mellitus is most likely nuanced and situation- and stage-dependent. To completely grasp IL-10's function in diabetes mellitus, further study is required..

Conclusion

IL-10 is synthesized by almost all leukocytes and secreted by monocytes. Macrophages and monocytes are impeded in their antigen-presenting duties by IL-10 which is inhibited by the pro-inflammatory cytokine production generated by IFN- and LPS and Stimulating effect on a variety of immunological cells. Human melanoma cells express IL-10 as a growth factor and contributes much to the etiology of many noninfectious illnesses, including Lupus erythematosus and melanoma. Occurrence of diabetic is associated with multiple polymorphisms located within the IL-10 gene.

References

1. Abdolmaleki, F., Gheibi Hayat, S. M., Bianconi, V., Johnston, T. P., & Sahebkar, A. (2019). Atherosclerosis and immunity: A perspective. *Trends in Cardiovascular Medicine*, *29*(6), 363–371. https://doi.org/10.1016/J.TCM.2018.09.017
2. Almolakab, Z. M., El-Nesr, K. A., Mohamad, E. H., Elkaffas, R., & Nabil, A. (2022). Gene polymorphisms of interleukin 10 (− 819 C/T and − 1082 G/A) in women with ovarian cancer. *Beni-Suef University Journal of Basic and Applied Sciences*, *11*(1), 1–16. https://doi.org/10.1186/S43088-022-00321-0/TABLES/5
3. Amarante-Mendes, G. P., Adjemian, S., Branco, L. M., Zanetti, L. C., Weinlich, R., & Bortoluci, K. R. (2018). Pattern recognition receptors and the host cell death molecular machinery. *Front. Immunol.*, *9*(OCT), 2379. https://doi.org/10.3389/fimmu.2018.02379
4. Amin, M. N., Siddiqui, S. A., Ibrahim, M., Hakim, M. L., Ahammed, Md. S., Kabir, A., & Sultana, F. (2020). Inflammatory cytokines in the pathogenesis of cardiovascular disease and cancer. *SAGE Open Medicine*, *8*, 205031212096575. https://doi.org/10.1177/20503121209657752/ASSET/IMAGES/LARGE/10.1177_2050312120965752-FIG2.JPEG
5. Asami, J., & Shimizu, T. (2021). Structural and functional understanding of the toll-like receptors. *Protein Sci.*, *30*(4), 761–772. https://doi.org/10.1002/pro.4043
6. Association, A. D. (2009). Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care*, *32*(Suppl 1), S62. https://doi.org/10.2337/DC09-S062
7. Bridgewood, A., & Publisher, C. D. (n.d.). *Psoriasis activation of cells important in cardiovascular disease Item Type Thesis*. Retrieved February 28, 2023, from http://hdl.handle.net/10454/17414
8. Briukhovetska, D., Dörr, J., Endres, S., Libby, P., Dinarello, C. A., & Kobold, S. (2021). Interleukins in cancer: from biology to therapy. *Nature Reviews Cancer*, *21*(8), 481–499. https://doi.org/10.1038/S41568-021-00363-Z
9. Cardiovascular disease and risk management. (2017). *Diabetes Care*, *40*, S75–S87. https://doi.org/10.2337/DC17-S012
10. Carty, M., Guy, C., & Bowie, A. G. (2021). Detection of viral infections by innate immunity. *Biochem. Pharmacol.*, *183*, 114316. https://doi.org/10.1016/j.bcp.2020.114316
11. Catalán, D., Mansilla, M. A., Ferrier, A., Soto, L., Oleinika, K., Aguillón, J. C., & Aravena, O. (2021). Immunosuppressive Mechanisms of Regulatory B Cells. *Frontiers in Immunology*, *12*, 654. https://doi.org/10.3389/FIMMU.2021.611795/BIBTEX
12. Correale, J., Marrodan, M., & Ysrraelit, M. C. (2019). Mechanisms of Neurodegeneration and Axonal Dysfunction in Progressive Multiple Sclerosis. *Biomedicines 2019, Vol. 7, Page 14*, *7*(1), 14. https://doi.org/10.3390/BIOMEDICINES7010014
13. El-Zayat, S. R., Sibaii, H., & Mannaa, F. A. (2019). Toll-like receptors activation, signaling, and targeting: an overview. *Bull. Natl Res. Cent.*, *43*(1), 187. https://doi.org/10.1186/s42269-019-0227-2
14. Fan, W. (2017). Epidemiology in diabetes mellitus and cardiovascular disease. *Cardiovascular Endocrinology*, *6*(1), 8. https://doi.org/10.1097/XCE.0000000000000116
15. Fass, D., & Thorpe, C. (2018). Chemistry and Enzymology of Disulfide Cross-linking in Proteins. *Chemical Reviews*, *118*(3), 1169.

https://doi.org/10.1021/ACS.CHEMREV.7B00123
16. Fitzgerald, K. A., & Kagan, J. C. (2020). Toll-like receptors and the control of immunity. *Cell*, *180*(6), 1044–1066. https://doi.org/10.1016/j.cell.2020.02.041
17. Flammer, J., Neziraj, T., Rüegg, S., Pröbstel, A.-K., Ch, S. R., & Ch, A.-K. P. (2023). Immune Mechanisms in Epileptogenesis: Update on Diagnosis and Treatment of Autoimmune Epilepsy Syndromes. *Drugs 2023 83:2*, *83*(2), 135–158. https://doi.org/10.1007/S40265-022-01826-9
18. Genuth, S. M., Palmer, J. P., & Nathan, D. M. (2018). Classification and Diagnosis of Diabetes. *Diabetes in America, 3rd Edition*, *2*(4), 1–39. https://www.ncbi.nlm.nih.gov/books/NBK568014/
19. Giastas, P., Zouridakis, M., & Tzartos, S. J. (2018). Understanding structure–function relationships of the human neuronal acetylcholine receptor: insights from the first crystal structures of neuronal subunits. *British Journal of Pharmacology*, *175*(11), 1880. https://doi.org/10.1111/BPH.13838
20. Giri, B., Dey, S., Das, T., Sarkar, M., Banerjee, J., & Dash, S. K. (2018). Chronic hyperglycemia mediated physiological alteration and metabolic distortion leads to organ dysfunction, infection, cancer progression and other pathophysiological consequences: An update on glucose toxicity. *Biomedicine & Pharmacotherapy*, *107*, 306–328. https://doi.org/10.1016/J.BIOPHA.2018.07.157
21. Hanahan, D. (2022). Hallmarks of Cancer: New Dimensions. *Cancer Discovery*, *12*(1), 31–46. https://doi.org/10.1158/2159-8290.CD-21-1059
22. Hashad, I. M., Nosseir, H., Shaban, G. M., Abdel Rahman, M. F., & Gad, M. Z. (2021). Is there a correlation between -174(G/C) polymorphism of IL-6 gene and the incidence of acute myocardial infarction? *Journal of Genetic Engineering & Biotechnology*, *19*(1). https://doi.org/10.1186/S43141-021-00243-X
23. Hazrati, A., Soudi, S., Malekpour, K., Mahmoudi, M., Rahimi, A., Hashemi, S. M., & Varma, R. S. (2022). Immune cells-derived exosomes function as a double-edged sword: role in disease progression and their therapeutic applications. *Biomarker Research 2022 10:1*, *10*(1), 1–25. https://doi.org/10.1186/S40364-022-00374-4
24. Hong, N., Ku, S., Yuk, K., Johnston, T. V., Ji, G. E., & Park, M. S. (2021). Production of biologically active human interleukin-10 by Bifidobacterium bifidum BGN4. *Microbial Cell Factories*, *20*(1), 1–14. https://doi.org/10.1186/S12934-020-01505-Y/TABLES/2
25. Hou, K., Wu, Z. X., Chen, X. Y., Wang, J. Q., Zhang, D., Xiao, C., Zhu, D., Koya, J. B., Wei, L., Li, J., & Chen, Z. S. (2022). Microbiota in health and diseases. *Signal Transduction and Targeted Therapy 2022 7:1*, *7*(1), 1–28. https://doi.org/10.1038/s41392-022-00974-4
26. Jaśkiewicz, A., Domoradzki, T., & Pajak, B. (2020). Targeting the JAK2/STAT3 Pathway—Can We Compare It to the Two Faces of the God Janus? *International Journal of Molecular Sciences 2020, Vol. 21, Page 8261*, *21*(21), 8261. https://doi.org/10.3390/IJMS212182611
27. Kalra, S., Jena, B. N., & Yeravdekar, R. (2018). Emotional and Psychological Needs of People with Diabetes. *Indian Journal of Endocrinology and Metabolism*, *22*(5), 696. https://doi.org/10.4103/IJEM.IJEM_579_17
28. Kang, J., Liu, C. H., Lee, C. N., Li, H. Y., Yang, C. W., Huang, S. C., Lin, S. Y., & Jou, T. S. (2019). Novel Interleukin-10 Gene

Polymorphism Is Linked to Gestational Diabetes in Taiwanese Population. *Frontiers in Genetics*, *10*(FEB). https://doi.org/10.3389/FGENE.2019.00089

29. Kany, S., Vollrath, J. T., & Relja, B. (2019). Cytokines in Inflammatory Disease. *International Journal of Molecular Sciences*, *20*(23). https://doi.org/10.3390/IJMS20236008
30. Kosiborod, M., Gomes, M. B., Nicolucci, A., Pocock, S., Rathmann, W., Shestakova, M. V., Watada, H., Shimomura, I., Chen, H., Cid-Ruzafa, J., Fenici, P., Hammar, N., Surmont, F., Tang, F., & Khunti, K. (2018). Vascular complications in patients with type 2 diabetes: Prevalence and associated factors in 38 countries (the DISCOVER study program). *Cardiovascular Diabetology*, *17*(1), 1–13. https://doi.org/10.1186/S12933-018-0787-8/FIGURES/2
31. Kyrou, I., Tsigos, C., Mavrogianni, C., Cardon, G., van Stappen, V., Latomme, J., Kivelä, J., Wikström, K., Tsochev, K., Nanasi, A., Semanova, C., Mateo-Gallego, R., Lamiquiz-Moneo, I., Dafoulas, G., Timpel, P., Schwarz, P. E. H., Iotova, V., Tankova, T., Makrilakis, K., & Manios, Y. (2020). Sociodemographic and lifestyle-related risk factors for identifying vulnerable groups for type 2 diabetes: A narrative review with emphasis on data from Europe. *BMC Endocrine Disorders*, *20*(1), 1–13. https://doi.org/10.1186/S12902-019-0463-3/FIGURES/1
32. Lin, X., & Li, H. (2021). Obesity: Epidemiology, Pathophysiology, and Therapeutics. *Frontiers in Endocrinology*, *12*. https://doi.org/10.3389/FENDO.2021.706978
33. Liu, G. Q., & Gack, M. U. (2020). Distinct and orchestrated functions of RNA sensors in innate immunity. *Immunity*, *53*(1), 26–42. https://doi.org/10.1016/j.immuni.2020.03.017
34. Loh, C. Y., Arya, A., Naema, A. F., Wong, W. F., Sethi, G., & Looi, C. Y. (2019). Signal transducer and activator of transcription (STATs) proteins in cancer and inflammation: Functions and therapeutic implication. *Frontiers in Oncology*, *9*(FEB), 48. https://doi.org/10.3389/FONC.2019.00048/BIBTEX
35. Madani, A. Y., Majeed, Y., Abdesselem, H. B., Agha, M. V., Vakayil, M., Al Sukhun, N. K., Halabi, N. M., Kumar, P., Hayat, S., Elrayess, M. A., Rafii, A., Suhre, K., & Mazloum, N. A. (2021). Signal Transducer and Activator of Transcription 3 (STAT3) Suppresses STAT1/Interferon Signaling Pathway and Inflammation in Senescent Preadipocytes. *Antioxidants 2021, Vol. 10, Page 334*, *10*(2), 334. https://doi.org/10.3390/ANTIOX10020334
36. Mahajan, R., El-Omar, E. M., Lissowska, J., Grillo, P., Rabkin, C. S., Baccarelli, A., Yeager, M., Sobin, L. H., Zatonski, W., Channock, S. J., Chow, W. H., & Hou, L. (2008). Genetic Variants in T Helper Cell Type 1, 2 and 3 Pathways and Gastric Cancer Risk in a Polish Population. *Japanese Journal of Clinical Oncology*, *38*(9), 626. https://doi.org/10.1093/JJCO/HYN075
37. Marshall, J. S., Warrington, R., Watson, W., & Kim, H. L. (2018). An introduction to immunology and immunopathology. *Allergy, Asthma and Clinical Immunology*, *14*(2), 1–10. https://doi.org/10.1186/S13223-018-0278-1/TABLES/4
38. Martin, N. M., & Griffin, D. E. (2018). Interleukin-10 Modulation of Virus Clearance and Disease in Mice with Alphaviral Encephalomyelitis. *Journal of Virology*, *92*(6). https://doi.org/10.1128/JVI.01517-17
39. Mascaux, C., Angelova, M., Vasaturo, A., Beane, J., Hijazi, K., Anthoine, G., Buttard, B., Rothe, F., Willard-Gallo, K.,

Haller, A., Ninane, V., Burny, A., Sculier, J. P., Spira, A., & Galon, J. (2019). Immune evasion before tumour invasion in early lung squamous carcinogenesis. *Nature*, *571*(7766), 570–575. https://doi.org/10.1038/S41586-019-1330-0

40. Minshawi, F., Lanvermann, S., McKenzie, E., Jeffery, R., Couper, K., Papoutsopoulou, S., Roers, A., & Muller, W. (2020a). The Generation of an Engineered Interleukin-10 Protein With Improved Stability and Biological Function. *Frontiers in Immunology*, *11*, 1794. https://doi.org/10.3389/FIMMU.2020.01794/BIBTEX
41. Minshawi, F., Lanvermann, S., McKenzie, E., Jeffery, R., Couper, K., Papoutsopoulou, S., Roers, A., & Muller, W. (2020b). The Generation of an Engineered Interleukin-10 Protein With Improved Stability and Biological Function. *Frontiers in Immunology*, *11*, 1794. https://doi.org/10.3389/FIMMU.2020.01794/BIBTEX
42. Molnar, V., Matišić, V., Kodvanj, I., Bjelica, R., Jeleč, Ž., Hudetz, D., Rod, E., Čukelj, F., Vrdoljak, T., Vidović, D., Starešinić, M., Sabalić, S., Dobričić, B., Petrović, T., Antičević, D., Borić, I., Košir, R., Zmrzljak, U. P., & Primorac, D. (2021). Cytokines and Chemokines Involved in Osteoarthritis Pathogenesis. *International Journal of Molecular Sciences 2021, Vol. 22, Page 9208*, *22*(17), 9208. https://doi.org/10.3390/IJMS22179208
43. Morris, R., Kershaw, N. J., & Babon, J. J. (2018). The molecular details of cytokine signaling via the JAK/STAT pathway. *Protein Science : A Publication of the Protein Society*, *27*(12), 1984. https://doi.org/10.1002/PRO.3519
44. Morris, R. M., Mortimer, T. O., & O'Neill, K. L. (2022). Cytokines: Can Cancer Get the Message? *Cancers*, *14*(9). https://doi.org/10.3390/CANCERS14092178
45. Murer, P., & Neri, D. (2019). Antibody-cytokine fusion proteins: a novel class of biopharmaceuticals for the therapy of cancer and of chronic inflammation. *New Biotechnology*, *52*, 42. https://doi.org/10.1016/J.NBT.2019.04.002
46. Oguntibeju, O. O. (2019). Type 2 diabetes mellitus, oxidative stress and inflammation: examining the links. *International Journal of Physiology, Pathophysiology and Pharmacology*, *11*(3), 45. /pmc/articles/PMC6628012/
47. Palmer, K. D., & Apovian, C. M. (2017). Obesity: Overview of medical treatments and interventions. *Nutrition in the Prevention and Treatment of Disease*, 477–498. https://doi.org/10.1016/B978-0-12-802928-2.00022-9
48. Pennati, A., Ng, S., Wu, Y., Murphy, J. R., Deng, J., Rangaraju, S., Asress, S., Blanchfield, J. L., Evavold, B., & Galipeau, J. (2016). Regulatory B Cells Induce Formation of IL-10-Expressing T Cells in Mice with Autoimmune Neuroinflammation. *The Journal of Neuroscience*, *36*(50), 12598. https://doi.org/10.1523/JNEUROSCI.1994-16.2016
49. Peruzzaro, S. T., Andrews, M. M. M., Al-Gharaibeh, A., Pupiec, O., Resk, M., Story, D., Maiti, P., Rossignol, J., & Dunbar, G. L. (2019). Transplantation of mesenchymal stem cells genetically engineered to overexpress interleukin-10 promotes alternative inflammatory response in rat model of traumatic brain injury 11 Medical and Health Sciences 1109 Neurosciences. *Journal of Neuroinflammation*, *16*(1). https://doi.org/10.1186/S12974-018-1383-2
50. Pestovsky, Y. S., & Martínez-Antonio, A. (2019). *Drug Designing & Intellectual Properties International Journal The Synthesis of Alginate Microparticles and Nanoparticles*.

https://doi.org/10.32474/DDIPIJ.2019.03.000155

51. Pillon, N. J., Loos, R. J. F., Marshall, S. M., & Zierath, J. R. (2021). Metabolic consequences of obesity and type 2 diabetes: Balancing genes and environment for personalized care. *Cell*, *184*(6), 1530. https://doi.org/10.1016/J.CELL.2021.02.012
52. Porro, C., Cianciulli, A., & Panaro, M. A. (2020). The Regulatory Role of IL-10 in Neurodegenerative Diseases. *Biomolecules 2020, Vol. 10, Page 1017*, *10*(7), 1017. https://doi.org/10.3390/BIOM10071017
53. Poznyak, A., Grechko, A. V., Poggio, P., Myasoedova, V. A., Alfieri, V., & Orekhov, A. N. (2020). The Diabetes Mellitus–Atherosclerosis Connection: The Role of Lipid and Glucose Metabolism and Chronic Inflammation. *International Journal of Molecular Sciences*, *21*(5). https://doi.org/10.3390/IJMS21051835
54. Qiu, Y., Su, M., Liu, L., Tang, Y., Pan, Y., & Sun, J. (2021). Clinical application of cytokines in cancer immunotherapy. *Drug Design, Development and Therapy*, *15*, 2269–2287. https://doi.org/10.2147/DDDT.S308578
55. Regina, C. C., Mu'ti, A., & Fitriany, E. (2022). Diabetes Mellitus Type 2. *Verdure: Health Science Journal*, *3*(1), 8–17. https://www.ncbi.nlm.nih.gov/books/NBK513253/
56. S. Waters, R., Perry, J. S. A., Han, S. P., Bielekova, B., & Gedeon, T. (2018). The effects of interleukin-2 on immune response regulation. *Mathematical Medicine and Biology : A Journal of the IMA*, *35*(1), 79. https://doi.org/10.1093/IMAMMB/DQW021
57. Salari, N., Mansouri, K., Hosseinian-Far, A., Ghasemi, H., Mohammadi, M., Jalali, R., & Vaisi-Raygani, A. (2021). The effect of polymorphisms (174G> C and 572C> G) on the Interleukin-6 gene in coronary artery disease: a systematic review and meta-analysis. *Genes and Environment*, *43*(1). https://doi.org/10.1186/S41021-021-00172-8
58. Sartorius, R., Trovato, M., Manco, R., D'Apice, L., & De Berardinis, P. (2021). Exploiting viral sensing mediated by Toll-like receptors to design innovative vaccines. *Npj Vaccines 2021 6:1*, *6*(1), 1–15. https://doi.org/10.1038/s41541-021-00391-8
59. Schoggins, J. W. (2019). Interferon-stimulated genes: what do they all do? *Annu. Rev. Virol.*, *6*, 567–584. https://doi.org/10.1146/annurev-virology-092818-015756
60. Schülke, S. (2018). Induction of interleukin-10 producing dendritic cells as a tool to suppress allergen-specific T helper 2 responses. *Frontiers in Immunology*, *9*(MAR). https://doi.org/10.3389/FIMMU.2018.00455
61. Smith, M. K., Pai, J., Panaccione, R., Beck, P., Ferraz, J. G., & Jijon, H. (2019). Crohn's-like disease in a patient exposed to anti-Interleukin-17 blockade (Ixekizumab) for the treatment of chronic plaque psoriasis: a case report. *BMC Gastroenterology*, *19*(1), 162. https://doi.org/10.1186/S12876-019-1067-0/FIGURES/2
62. Sun, H., Wu, Y., Zhang, Y., & Ni, B. (2021). IL-10-Producing ILCs: Molecular Mechanisms and Disease Relevance. *Frontiers in Immunology*, *12*, 979. https://doi.org/10.3389/FIMMU.2021.650200/BIBTEX
63. Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA: A Cancer Journal for*

Clinicians, *71*(3), 209–249. https://doi.org/10.3322/CAAC.21660

64. Taban, Q., Mumtaz, P. T., Masoodi, K. Z., Haq, E., & Ahmad, S. M. (2022). Scavenger receptors in host defense: from functional aspects to mode of action. *Cell Communication and Signaling 2021 20:1*, *20*(1), 1–17. https://doi.org/10.1186/S12964-021-00812-0
65. Tarique, M., Naz, H., Saini, C., Suhail, M., Shankar, H., Khanna, N., & Sharma, A. (2020). Association of IL-10 Gene Polymorphism With IL-10 Secretion by CD4 and T Regulatory Cells in Human Leprosy. *Frontiers in Immunology*, *11*. https://doi.org/10.3389/FIMMU.2020.01974
66. Trifunović, J., Miller, L., Debeljak, Ž., & Horvat, V. (2015). Pathologic patterns of interleukin 10 expression – A review. *Biochemia Medica*, *25*(1), 36. https://doi.org/10.11613/BM.2015.004
67. Vazquez, M. I., Catalan-Dibene, J., & Zlotnik, A. (2015). B cells responses and cytokine production are regulated by their immune microenvironment. *Cytokine*, *74*(2), 318. https://doi.org/10.1016/J.CYTO.2015.02.007
68. Vijay, K. (2018). Toll-like receptors in immunity and inflammatory diseases: past, present, and future. *Int. Immunopharmacol.*, *59*, 391–412. https://doi.org/10.1016/j.intimp.2018.03.002
69. Wang, X., Wong, K., Ouyang, W., & Rutz, S. (2019). Targeting IL-10 Family Cytokines for the Treatment of Human Diseases. *Cold Spring Harbor Perspectives in Biology*, *11*(2), a028548. https://doi.org/10.1101/CSHPERSPECT.A028548
70. Yap, H. Y., Tee, S. Z. Y., Wong, M. M. T., Chow, S. K., Peh, S. C., & Teow, S. Y. (2018). Pathogenic Role of Immune Cells in Rheumatoid Arthritis: Implications in Clinical Treatment and Biomarker Development. *Cells*, *7*(10). https://doi.org/10.3390/CELLS7100161
71. Yuan, K., Li, X., Lu, Q., Zhu, Q., Jiang, H., Wang, T., Huang, G., & Xu, A. (2019). Application and mechanisms of triptolide in the treatment of inflammatory diseases-a review. *Frontiers in Pharmacology*, *10*, 1469. https://doi.org/10.3389/FPHAR.2019.01469/BIBTEX
72. Zhang, Y., Yang, W., Li, W., & Zhao, Y. (2021). NLRP3 Inflammasome: Checkpoint Connecting Innate and Adaptive Immunity in Autoimmune Diseases. *Frontiers in Immunology*, *12*, 4166. https://doi.org/10.3389/FIMMU.2021.732933/BIBTEX